임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 1상모집 예정· Large B-cell LymphomaGolcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
협력: BMS
- 1상모집 중· Diffuse Pleural MesotheliomaA Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
협력: BMS
- 1상모집 중· Colorectal CancerA Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
협력: BMS
- 1상모집 중· Rheumatoid ArthritisA Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
리드: BMS
- 1상모집 중· Healthy VolunteersA Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants
리드: BMS
- 1상모집 중· Renal Cell CarcinomaA First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
리드: BMS
- 1상모집 중· Healthy VolunteersA Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
리드: BMS
- 1상모집 중· Advanced Solid TumorsA Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
리드: BMS
- 1상모집 중· Healthy VolunteersA Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin
협력: BMS
- 1상모집 중· Refractory Autoimmune DiseasesA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
리드: BMS
- 1상모집 중· SchizophreniaA Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
리드: BMS
- 1상모집 중· Multiple MyelomaA Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
협력: BMS
- 1상모집 중· Advanced Solid TumorA Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
리드: BMS
- 1상모집 중단 (진행 중)· Small Cell Lung CarcinomaA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
리드: BMS
- 1상모집 중· Advanced Malignant TumorsA Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
리드: BMS
- 1상모집 중· Advanced Solid Tumors With Homozygous MTAP DeletionA Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
리드: BMS
- 1상모집 중단 (진행 중)· Advanced Solid TumorsA Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
리드: BMS
- 1상모집 중· High-grade Serous Ovarian Carcinoma (HGSOC)A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
리드: BMS
- 1상모집 중· B-Cell Non-Hodgkin Lymphoma-RecurrentCC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
협력: BMS
- 1상모집 중· Relapsed and/or Refractory Multiple MyelomaA Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
리드: BMS
- 1상모집 중· Metastatic Castration-resistant Prostate CancerA Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
리드: BMS
- 1상모집 중· Systemic Lupus ErythematosusA Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
리드: BMS
- 1상모집 중단 (진행 중)· DLBCL - Diffuse Large B Cell LymphomaLow Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
협력: BMS
- 1상모집 중· Multiple MyelomaA Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
협력: BMS
- 1상모집 중단 (진행 중)· Classical Hodgkin LymphomaAutologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
협력: BMS
- 1상모집 중단 (진행 중)· Multiple MyelomaCPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
협력: BMS
- 1상모집 중· Solid TumorStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
협력: BMS
- 1상모집 중단 (진행 중)· Hepatocellular CarcinomaFeasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
협력: BMS
- 1상모집 중단 (진행 중)· Advanced Solid TumorStudy of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
협력: BMS
- 1상모집 중단 (진행 중)· Pancreatic Ductal AdenocarcinomaA Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
협력: BMS
- 1상모집 중단 (진행 중)· Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
협력: BMS
- 1상모집 중단 (진행 중)· Recurrent GlioblastomaIL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
협력: BMS
- 1상모집 중단 (진행 중)· Malignant Pleural MesotheliomaA Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
협력: BMS
- 1상모집 중단 (진행 중)· OsteosarcomaNivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
협력: BMS
- 1상모집 중단 (진행 중)· Pathologic Stage IIIB Cutaneous Melanoma AJCC v8VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
협력: BMS
- 1상모집 중단 (진행 중)· Follicular LymphomaNivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
협력: BMS
- 1상모집 중단 (진행 중)· Gastric CancerNivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
협력: BMS
- 1상모집 중단 (진행 중)· Chronic Lymphocytic Leukemia (CLL)A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
협력: BMS
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.